Sageworth Trust’s Genmab GMAB Stock Holding History

Sageworth Trust’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-307	Closed	-$11.6K	–	222
2023 Q1	$11.6K	Buy	+307	New	+$11.8K	﹤0.01%	270

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sageworth Trust's GMAB Position: Q2 2023 in Review

Sageworth Trust sold out of Genmab (GMAB) in Q2 2023, closing a stake of 307 shares — an estimated $11.6K sold.

Sageworth Trust first reported a position in GMAB in Q1 2023 and held it in 1 quarter. The position peaked at $11.6K in Q1 2023. 213 funds tracked by Wall St. Rank hold GMAB as of Q2 2023.

Sageworth Trust reported no remaining Genmab position as of Q2 2023 after selling out during the quarter.
Sageworth Trust sold 307 Genmab shares in Q2 2023, an estimated $11.6K.
Sageworth Trust first reported a position in Genmab in Q1 2023 and held it in 1 quarter.
Sageworth Trust's Genmab position peaked at $11.6K in Q1 2023.
213 funds tracked by Wall St. Rank held Genmab as of Q2 2023.

Based on Sageworth Trust's 13F filing for Q2 2023, filed 26 Jul 2023.